Treatment of Demodex Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle

References

• Karakurt Y, Zeytun E. Evaluation of the efficacy of tea tree oil on the density of demodex mites (acari: demodicidae) and ocular symptoms in patients with demodectic blepharitis. J Parasitol. 2018;104(5):473–478. doi:10.1645/18-46.
   PubMed Web of Science ®Google Scholar
• Trattler W, Karpecki P, Rapoport Y, et al. The prevalence of Demodex blepharitis in US eye care clinic patients as determined by collarettes: A pathognomonic sign. Clin Ophthalmol. 2022;16:1153–1164.
   Google Scholar
• Holzchuh FG, Hida RY, Moscovici BK, et al. Clinical treatment of ocular Demodex folliculorum by systemic ivermectin. Am J Ophthalmol. 2011;151(6):1030–1034 e1031.
   PubMed Web of Science ®Google Scholar
• Savla K, Le JT, Pucker AD. Tea tree oil for Demodex blepharitis. Cochrane Database Syst Rev. 2020;6:CD013333. doi:10.1002/14651858.CD013333.pub2.
   PubMed Web of Science ®Google Scholar
• Fromstein SR, Harthan JS, Patel J, Opitz DL. Demodex blepharitis: clinical perspectives. Clin Optom (Auckl). 2018;10:57–63. doi:10.2147/OPTO.S142708.
   PubMed Web of Science ®Google Scholar
• Navel V, Mulliez A, Benoist d’Azy C, et al. Efficacy of treatments for Demodex blepharitis: a systematic review and meta-analysis. Ocul Surf. 2019;17(4):655–669. doi:10.1016/j.jtos.2019.06.004.
   PubMed Web of Science ®Google Scholar
• Suresha A, Sadhwini M. Role of demodex infestation in blepharitis and coconut oil as a treatment option. Indian J Clin Exp Ophthalmol. 2020;6(2):270–275. doi:10.18231/j.ijceo.2020.058.
   Google Scholar
• Lacey N, Kavanagh K, Tseng SC. Under the lash: Demodex mites in human diseases. Biochem (Lond). 2009;31:2–6.
   PubMedGoogle Scholar
• Messaoud R, El Fekih L, Mahmoud A, et al. Improvement in ocular symptoms and signs in patients with Demodex anterior blepharitis using a novel terpinen-4-ol (2.5%) and hyaluronic acid (0.2%) cleansing wipe. Clin Ophthalmol. 2019;13:1043–1054. doi:10.2147/OPTH.S198585.
   PubMed Web of Science ®Google Scholar
• Luo X, Li J, Chen C, Tseng S, Liang L. Ocular demodicosis as a potential cause of ocular surface inflammation. Cornea. 2017;36(Suppl 1):S9–S14. doi:10.1097/ICO.0000000000001361.
   PubMed Web of Science ®Google Scholar
• Liu J, Sheha H, Tseng SC. Pathogenic role of Demodex mites in blepharitis. Curr Opin Allergy Clin Immunol. 2010;10(5):505–510. doi:10.1097/ACI.0b013e32833df9f4.
   PubMed Web of Science ®Google Scholar
• Zhang X-B, Ding Y-H, He W. The association between demodex infestation and ocular surface manifestations in meibomian gland dysfunction. Int J Ophthalmol. 2018;11(4):589. doi:10.18240/ijo.2018.04.08.
   PubMed Web of Science ®Google Scholar
• Erbagci Z, Erbagci I, Erkilic S. High incidence of demodicidosis in eyelid basal cell carcinomas. Int J Dermatol. 2003;42(7):567–571. doi:10.1046/j.1365-4362.2003.01928.x.
   PubMed Web of Science ®Google Scholar
• Huang Y, He H, Sheha H, Tseng SC. Ocular demodicosis as a risk factor of pterygium recurrence. Ophthalmology. 2013;120(7):1341–1347. doi:10.1016/j.ophtha.2013.01.001.
   PubMed Web of Science ®Google Scholar
• Liang L, Ding X, Tseng SC. High prevalence of demodex brevis infestation in chalazia. Am J Ophthalmol. 2014;157(2):342–348 e341. doi:10.1016/j.ajo.2013.09.031.
   PubMed Web of Science ®Google Scholar
• Zhao YE, Wu L, Peng Y, Cheng H. Retrospective analysis of the association between Demodex infestation and rosacea. Arch Dermatol. 2010;146(8):896–902. doi:10.1001/archdermatol.2010.196.
   PubMedGoogle Scholar
• Filho PA, Hazarbassanov RM, Grisolia AB, Pazos HB, Kaiserman I, Gomes JA. The efficacy of oral ivermectin for the treatment of chronic blepharitis in patients tested positive for Demodex spp. Br J Ophthalmol. 2011;95(6):893–895. doi:10.1136/bjo.2010.201194.
   PubMed Web of Science ®Google Scholar
• Gao YY, Di Pascuale MA, Li W, et al. High prevalence of Demodex in eyelashes with cylindrical dandruff. Invest Ophthalmol Vis Sci. 2005;46(9):3089–3094. doi:10.1167/iovs.05-0275.
   PubMed Web of Science ®Google Scholar
• Kabat AG. Hypochlorous acid solution (Avenova((R))) is not demodicidal. Clin Optom (Auckl). 2018;10:115–117. doi:10.2147/OPTO.S182534.
   PubMed Web of Science ®Google Scholar
• Kim JH, Chun YS, Kim JC. Clinical and immunological responses in ocular demodecosis. J Korean Med Sci. 2011;26(9):1231–1237. doi:10.3346/jkms.2011.26.9.1231.
   PubMed Web of Science ®Google Scholar
• Koo H, Kim TH, Kim KW, Wee SW, Chun YS, Kim JC. Ocular surface discomfort and Demodex: effect of tea tree oil eyelid scrub in Demodex blepharitis. J Korean Med Sci. 2012;27(12):1574–1579. doi:10.3346/jkms.2012.27.12.1574.
   PubMed Web of Science ®Google Scholar
• Ngo W, Jones L, Bitton E. Short-term comfort responses associated with the use of eyelid cleansing products to manage Demodex folliculorum. Eye Contact Lens. 2018;44(Suppl 2):S87–S92. doi:10.1097/ICL.0000000000000415.
   PubMed Web of Science ®Google Scholar
• Salem DA, El-Shazly A, Nabih N, El-Bayoumy Y, Saleh S. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis. 2013;17(5):e343–347. doi:10.1016/j.ijid.2012.11.022.
   PubMed Web of Science ®Google Scholar
• Tighe S, Gao -Y-Y, Tseng SC. Terpinen-4-ol is the most active ingredient of tea tree oil to kill Demodex mites. Transl Vis Sci Technol. 2013;2(7):2. doi:10.1167/tvst.2.7.2.
   PubMed Web of Science ®Google Scholar
• Zhang AC, Muntz A, Wang MTM, Craig JP, Downie LE. Ocular Demodex: a systematic review of the clinical literature. Ophthalmic Physiol Opt. 2020;40(4):389–432. doi:10.1111/opo.12691.
   PubMed Web of Science ®Google Scholar
• Chen D, Wang J, Sullivan DA, Kam WR, Liu Y. Effects of terpinen-4-ol on meibomian gland epithelial cells in vitro. Cornea. 2020;39(12):1541–1546. doi:10.1097/ICO.0000000000002506.
   PubMed Web of Science ®Google Scholar
• Toutain CE, Seewald W, Jung M. The intravenous and oral pharmacokinetics of lotilaner in dogs. Parasit Vectors. 2017;10(1):522. doi:10.1186/s13071-017-2475-z.
   PubMedGoogle Scholar
• Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Collarette elimination and demodex mite eradication with topical lotilaner ophthalmic solution, 0.25%. J Ocul Pharmacol Ther. 2021;37(8):479–484. doi:10.1089/jop.2021.0011.
   PubMed Web of Science ®Google Scholar
• Salinas RG, Karpecki P, Yeu E, et al. Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: a randomized, controlled, double-masked clinical trial. Cont Lens Anterior Eye. 2021:101492. doi:10.1016/j.clae.2021.101492.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Salinas R, Yeu E, Holdbrook M, et al. Safety and efficacy of topical lotilaner ophthalmic solution 0.25% for the treatment of demodex blepharitis: a pilot study. J Ophthalmol. 2021;2021:3862684. doi:10.1155/2021/3862684.
   PubMed Web of Science ®Google Scholar
• Hirsch-Hoffmann S, Kaufmann C, Banninger PB, Thiel MA. Treatment options for demodex blepharitis: patient choice and efficacy. Klin Monbl Augenheilkd. 2015;232(4):384–387. doi:10.1055/s-0035-1545780.
   PubMed Web of Science ®Google Scholar
• Tarsus Pharmaceuticals. Tarsus releases data from io and Europa trials for TP-03 to treat demodex blepharitis and begins enrollment and treatment in phase 2b/3 Saturn-1 trial [Press release]. 2020, October 6. https://ir.tarsusrx.com/news-releases/news-release-details/tarsus-releases-data-io-and-europa-trials-tp-03-treat-demodex. Accessed May 21, 2021.
   Google Scholar
• Casas C, Paul C, Lahfa M, et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol. 2012;21(12):906–910. doi:10.1111/exd.12030.
   PubMed Web of Science ®Google Scholar
• Kubanov A, Gallyamova Y, Kravchenko A. Clinical picture, diagnosis and treatment of rosacea, complicated by Demodex mites. Dermatol Reports. 2019;11(1):7675. doi:10.4081/dr.2019.7675.
   PubMed Web of Science ®Google Scholar
• Milner MS, Beckman KA, Luchs JI, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders–new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;28(Suppl 1):3. doi:10.1097/01.icu.0000512373.81749.b7.
   PubMedGoogle Scholar
• Raval Y, Gomes PJ, Abelson MB. Standardized lid margin redness scale for blepharitis. Invest Ophthalmol Vis Sci. 2019;60:6270.
   Web of Science ®Google Scholar
• Nichols KK, Holland E, Toyos MM, et al. Ocular comfort assessment of lifitegrast ophthalmic solution 5.0% in OPUS-3, a Phase III randomized controlled trial. Clin Ophthalmol. 2018;12:263. doi:10.2147/OPTH.S152841.
   PubMed Web of Science ®Google Scholar
• Arita R, Fukuoka S. Non‐pharmaceutical treatment options for meibomian gland dysfunction. Clin Exp Optom. 2020;103(6):742–755. doi:10.1111/cxo.13035.
   PubMed Web of Science ®Google Scholar